Stem Cells - The hype and the hope - Business opportunities and forecasts

The news has been full of industry developments and financial investments in stem cell research in recent weeks. Your company must be aware of the latest developments immediately.

Researchers Find New Source For Stem Cells That Could End Debate

Brain stem cells against cancer?

'Bio-ink' Printer Transforms Stem Cells

US delegation divided over stem cells

Stem cells are without doubt the most controversial area of science at the moment. The world markets have latched onto the potential offered by stem cells to modern medicine and, as a result, the research is in the public eye on an almost daily basis. Are you fully informed of the market potential of stem cell work? Do you know which companies and research organisations you must work with now? This report tells you.

So what is all the controversy about? And what products are we likely to see, in what areas and when, if stem cell work continues at pace?

The potential lies in that given the right circumstances, embryonic stem cells could be used to create new tissues and organs for patients whose tissues or organs have been destroyed, damaged, diseased or have simply aged. For example, for patients with heart failure, the aim would be to create new, tailor-made cardiac cells to replace the damaged tissue. For patients with spinal injury, research would be directed at the creation of new spinal tissue which could replace injured nerve tissue allowing the patient to regain mobility in paralysed limbs. What part will your company play in this? Find out today.

However, much of this global effort is currently being thwarted by issues that are restraining progress in a way that has been unparalleled in the biotech and pharmaceutical sector. How can your company get around these problems? What opportunities are there for you? Find out today.

With these obvious frustrations, it is perhaps surprising that so much work on embryonic stem cells, and to a lesser extent adult stem cells, continues but governments and companies around the world are evolving new strategies to overcome these limitations.

One successful product launch will change the face of modern medicine from a situation where treatments and alleviation of suffering are the norm to one where replacement parts are offered routinely.

This unique one-stop-shop of a report is the premier business analysis of the market opportunities. Possible values to the market range from billions to perhaps nothing. If the one product launch fails to deliver or, worse, has damaging side-effects, then the market could just as easily collapse overnight. By reading one report you can put your company to the forefront of stem cell business knowledge.

Order your copy of this unique un-biased assessment, analysis, facts, figures, tables and charts of how your market will develop.

This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' of your competitors. You can not afford to be without this report from visiongain.

Organizations lists:

Aarstrom Biosciences Inc.

Acorda Therapeutics

Advanced BioHealing, Inc.

Advanced Cell Technology Inc.

Aldagen, Inc.

American Society of Plastic Surgeons

Amersham

Amgen

Angel BioTechnology

Ansary Center for Stem Cell Therapeutics

Arthritis Research Campaign, UK

AstraZeneca

Athersys

Axordia

Bart’s and The London NHS Trust, UK

BioE

Bioheart, Inc.

Biotechnology and Biological Sciences Research Council, UK

BrainStorm Cell Therapeutics

BresaGen

Burnham Institute for Medical Research

The California Family Bioethics Council

California Institute for Regenerative Medicine

Cellartis

CellCura

Cellerant

Cellular Dynamics International

The Cellulite Clinic

Center for Stem Cell and Regenerative Medicine, Ohio

Cordlife

Cythera/ Novocell

Cytori Therapeutics

Department of Health and Human Services, US

Epistem

ES Cell International (ESI)

European Patent Office

Fisher

Food and Drug Administration, US

Gamida

Genentech

Genzyme

Geron

GlobalStem Inc

Human Fertilisation and Embryology Authority, UK

Illinois Regenerative Medicine Institute

Institute for Regenerative Medicine

Intercytex

Invitrogen

The Joan and Sanford I Weill Medical Centre

Johns Hopkins University

Johnson and Johnson

Juvenile Diabetes Research Foundation

King’s College, London

Maryland Technology Development Corporation

Mediatech Inc

Medical Research Council, UK

Medra Clinic

Memorial Sloan-Kettering Cancer Centre

Merck

Mesoblast Limited

Nabi Medspa

The National Academies, US

The National Institutes of Health, US

National Health Service

National Science Foundation

National Tax Limitation Committee

Neuronova

New Jersey Stem Cell Institute

Novartis AG

Novathera

Novocell

Odontis

Organogenesis

Osiris

Pluristem

RegenTec

Reinnervate

Reliance Life Sciences

ReNeuron

Renovo

RhinoCyte, Inc.

Rockefeller University

Roslin Institute

Royal College of Obstetrics and Gynaecologists, UK

Schering AG

Sigma-Aldrich

Smith and Nephew

The Starr Foundation

Stem Cells Inc.

Stem Cell Innovations

StemCell Technologies Inc.

Stem Cell Therapeutics Corp

Stem Cell Sciences

StemCo Biomedical

Stempeutics

Tengion

TheraVitae

Titan Pharmaceuticals Inc.

Tulane University

UK Stem Cell Bank

United States Patents and Trademark Office

University of Maryland

University of Massachusetts

University of Newcastle

University of San Francisco, California

University of Texas Health Centre

University of Wisconsin

Vesta Therapeutics Inc.

Viacell

Vistagen Therapeutics Inc.

Wellcome Trust, UK

WiCell Research Institute, US

Wisconsin Alumni Research Foundation

Wisconsin State Laboratory of Hygiene

Wolfson Foundation, UK

World Health Organisation

Lead Analyst: Dr Eleanor Kennedy Publication Date: 23/01/07 Pages: 169

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.
Table of Contents

Price
Single User Licence $9998.00
Department Licence 5 Users $21998.00
Company-wide Intranet Licence $41998.00